Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS

被引：1
|
作者：
Peck-Radosavljevic, M. [1 ,2 ]
Kudo, M. [3 ]
Lee, H. C. [4 ]
Cheng, A. -Lii [5 ]
Nakajima, K. [6 ]
Raoul, J. -L. [7 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Klinikum Klagenfurt Worthersee, Klagenfurt, Austria
[3] Kindai Univ, Fac Med, Osaka, Japan
[4] Asan Med Ctr, Seoul, South Korea
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Inst Cancerol Ouest, Digest Oncol, Nantes, France
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30614-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-164
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [1] Outcomes of Patients (pts) with Hepatocellular Carcinoma (HCC) Treated with Transarterial Chemoembolization (TACE): Global OPTIMIS Final Analysis
    Peck-Radosavljevic, Markus
    Kudo, Masatoshi
    Raoul, Jean-Luc
    Lee, Han Chu
    Decaens, Thomas
    Heo, Jeong
    Lin, Shi-Ming
    Shan, Hong
    Yang, Yefa
    Bayh, Inga
    Nakajima, Keiko
    Cheng, Ann-Lii
    HEPATOLOGY, 2018, 68 : 167A - 168A
  • [2] Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
    Peck-Radosavljevic, Markus
    Kudo, Masatoshi
    Raoul, Jean-Luc
    Lee, Han Chu
    Decaens, Thomas
    Heo, Jeong
    Lin, Shi-Ming
    Shan, Hong
    Yang, Yefa
    Bayh, Inga
    Nakajima, Keiko
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Yue Han
    Guang Cao
    Bin Sun
    Jian Wang
    Dong Yan
    Haifeng Xu
    Qinsheng Shi
    Zechuan Liu
    Weihua Zhi
    Liang Xu
    Bojun Liu
    Yinghua Zou
    BMC Gastroenterology, 21
  • [4] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [5] Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience
    Lin, Po-Ting
    Teng, Wei
    Jeng, Wen-Juei
    Hsieh, Yi-Chung
    Hung, Chen-Fu
    Huang, Chien-Hao
    Lui, Kar-Wai
    Chen, Yi-Cheng
    Lin, Chen-Chun
    Lin, Chun-Yen
    Sheen, I-Shyan
    Lin, Shi-Ming
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (09) : 1192 - 1199
  • [6] A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
    Lee, Jae Seung
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Seong, Jin Sil
    Han, Kwang-Hyub
    Kim, Do Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (01) : 24 - 32
  • [7] Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).
    Zhu, Haidong
    Lu, Jian
    Teng, Gao-Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 542 - 542
  • [8] Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis
    Peck-Radosavljevic, Markus
    Lee, Han Chu
    Kudo, Masatoshi
    Nakajima, Keiko
    Bayh, Inga
    Cheng, Ann-Lii
    Raoul, Jean-Luc
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E616 - E616
  • [9] Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization
    Flohr, Felix
    Harder, Jan
    Seufert, Jochen
    Blum, Hubert E.
    Spangenberg, Hans C.
    HEPATOLOGY, 2008, 47 (06) : 2144 - 2144
  • [10] Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization
    Xiao, Jun
    Li, Guojian
    Lin, Shuhan
    He, Ke
    Lai, Hao
    Mo, Xianwei
    Chen, Jiansi
    Lin, Yuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (03): : 1114 - 1123
12345